Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.
Bissonnette
Robert
R
Chen
Genhui
G
Bolduc
Chantal
C
Maari
Catherine
C
Lyle
Michael
M
Tang
Liren
L
Webster
John
J
Zhou
Youwen
Y
D000287:Administration, Topical; D000328:Adult; D001555:Benzene Derivatives / Q000008:administration & dosage / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome
D001555:Benzene Derivatives; D004337:Drug Carriers; D007155:Immunologic Factors